Risk of Changes in Pharmaceutical-Related Laws and Regulations
First written in FY2016. 19 of 21 entries say "Restated". Latest entry: FY2026.
Rohto Pharmaceutical moved to the "Worse" side of this theme in 2026, 1 year after the typical company in this theme (2025).
The whole theme swung hardest in 2020: 12 of 84 companies on the "Worse" side.
10 other companies' latest entry also says "Reframed".
- FY2026ReframedAnnual report
「The Group's businesses are affected by various domestic and overseas laws and regulations, including the Pharmaceuticals and Medical Devices Act, food-related laws and regulations, the Act against Unjustifiable Premiums and Misleading Representations, the Antimonopoly Act, the Act on the Protection of Personal Information, environmental laws and regulations, and import and export regulations in various countries and regions.」
The Company has reorganised the existing risk of changes in pharmaceutical-related laws and regulations as a comprehensive risk of changes in legal regulations and systems, encompassing food, labelling, competition law, personal information, environmental matters and import and export regulations. - FY2024-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」
The Company states that there have been no material changes to the business and other risks disclosed in the previous fiscal year, including the risk of changes in pharmaceutical-related laws and regulations. - FY2024-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」
The Company states that there have been no material changes to the business and other risks disclosed in the previous fiscal year, including the risk of changes in pharmaceutical-related laws and regulations. - FY2024-Q1RestatedAnnual report
「During the cumulative first quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」
The Company states that there have been no material changes to the business and other risks disclosed in the previous fiscal year, including the risk of changes in pharmaceutical-related laws and regulations. - FY2023-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」
The Company states that there have been no material changes regarding the risk of changes in pharmaceutical-related laws and regulations. - FY2023-Q1RestatedAnnual report
「During the cumulative first quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」
The Company states that there have been no material changes regarding the risk of changes in pharmaceutical-related laws and regulations. - FY2022-Q1RestatedAnnual report
「During the cumulative first quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」
The Company states that there have been no material changes from the previous fiscal year's disclosure regarding the risk of changes in pharmaceutical-related laws and regulations. - FY2021-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」
The Company states that there have been no material changes to the business and other risks, including the risk of changes in pharmaceutical-related laws and regulations. - FY2021-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」
The Company states that there have been no material changes to the business and other risks, including the risk of changes in pharmaceutical-related laws and regulations. - FY2021-Q1RestatedAnnual report
「During the cumulative first quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」
The Company states that there have been no material changes to the business and other risks, including the risk of changes in pharmaceutical-related laws and regulations. - FY2020-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」
The Company states that there have been no material changes to the business and other risks, including the risk of changes in pharmaceutical-related laws and regulations. - FY2020-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」
The Company states that there have been no material changes to the business and other risks, including the risk of changes in pharmaceutical-related laws and regulations. - FY2020-Q1RestatedAnnual report
「During the cumulative first quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」
The Company states that there have been no material changes to the business and other risks, including the risk of changes in pharmaceutical-related laws and regulations. - FY2019-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」
The Company states that there have been no material changes from the previous fiscal year's disclosure regarding the risk of changes in pharmaceutical-related laws and regulations. - FY2019-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」
The Company states that there have been no material changes to the business and other risks disclosed in the previous fiscal year, including the risk of changes in pharmaceutical-related laws and regulations. - FY2019-Q1RestatedAnnual report
「During the cumulative first quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」
The Company states that there have been no material changes from the previous fiscal year's disclosure regarding the risk of changes in pharmaceutical-related laws and regulations. - FY2018-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」
The Company states that there have been no material changes to the business and other risks disclosed in the previous fiscal year, including the risk of changes in regulations such as the Pharmaceuticals and Medical Devices Act. - FY2018-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」
The Company states that there have been no material changes to the business and other risks disclosed in the previous fiscal year, including the risk of changes in regulations such as the Pharmaceuticals and Medical Devices Act. - FY2018-Q1RestatedAnnual report
「During the cumulative first quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」
The Company states that there have been no material changes to the business and other risks disclosed in the previous fiscal year, including the risk of changes in pharmaceutical-related laws and regulations. - FY2017RestatedAnnual report
「The Group's businesses are affected by regulations under the Pharmaceuticals and Medical Devices Act and other applicable laws and regulations, including deregulation. If these regulations change in the future, they may affect operating performance and financial condition.」
The Company continues to disclose the risk of changes in regulations, including the Pharmaceuticals and Medical Devices Act. - FY2016First statedAnnual report
「The Group's businesses are affected by regulations under the Pharmaceuticals and Medical Devices Act and other applicable laws and regulations, including deregulation. If these regulations change in the future, they may affect operating performance and financial condition.」
The Company identifies as a risk the possibility that changes in regulations, including the Pharmaceuticals and Medical Devices Act, and regulatory deregulation may affect its business performance and financial position.